Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 7:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 132 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Coeliac Disease Clear all
Completed Phase 2 Interventional Results available

A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease

NCT06001177
View directory record Official record
Conditions
Celiac Disease, Coeliac Disease
Interventions
KAN-101, Placebo
Drug
Lead sponsor
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Industry
Eligibility
18 Years to 70 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
6
States / cities
Colorado Springs, Colorado • Hialeah Gardens, Florida • Miami, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jul 23, 2026, 7:42 PM EDT
Active, not recruiting Phase 2 Interventional

A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease

NCT06557772
View directory record Official record
Conditions
Coeliac Disease, Celiac Disease
Interventions
Amlitelimab, Placebo, SIGE, Gluten-free product (GFP)
Drug · Dietary Supplement
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
35
States / cities
Scottsdale, Arizona • Arcadia, California • Lancaster, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Jul 23, 2026, 7:42 PM EDT
Terminated Phase 4 Interventional Results available

Budesonide in Patients With Immune Mediated Enteropathies

NCT03866538
View directory record Official record
Conditions
Enteropathy, Celiac Disease, CVID Enteropathy, Collagenous Sprue, Autoimmune Enteropathy
Interventions
Withdrawal of Oral Budesonide
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Jul 23, 2026, 7:42 PM EDT
Completed No phase listed Observational

Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity

NCT03941184
View directory record Official record
Conditions
SCAD, Addison Disease, Ankylosing Spondylitis, Antiphospholipid Antibody Syndrome, Celiac Disease, Crohn Disease, Dermatomyositis, Polymyositis, Guillain-Barre Syndrome, Hepatitis, Autoimmune, Graves Disease, Hashimoto Thyroiditis, Multiple Sclerosis, Myasthenia Gravis, Pernicious Anemia, Polymyalgia Rheumatica, Primary Biliary Cirrhosis, Psoriasis, Rheumatoid Arthritis, Systemic Sclerosis, Sjögren Syndrome, Systemic Lupus Erythematosus, Takayasu Arteritis, Type 1 Diabetes Mellitus, Ulcerative Colitis, Uveitis, Vasculitis, Vitiligo, Raynaud
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 110 Years
Enrollment
114 participants
Timeline
1995 – 2020
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 22, 2020 · Synced Jul 23, 2026, 7:42 PM EDT
Completed No phase listed Observational

Fecal Calprotectin Collection Protocol

NCT03143517
View directory record Official record
Conditions
Inflammatory Bowel Diseases, Irritable Bowel Syndrome, Ulcerative Colitis, Crohn Disease, Indeterminate Colitis, Chronic Diarrhea, Celiac Disease, Diverticulitis, Abdominal Pain, Distension, Weight Loss, Food Intolerance, Constipation
Interventions
Stool collection
Diagnostic Test
Lead sponsor
DiaSorin Inc.
Industry
Eligibility
4 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
13
States / cities
Dothan, Alabama • Little Rock, Arkansas • Mission Hills, California + 10 more
Source: ClinicalTrials.gov public record
Updated Feb 6, 2019 · Synced Jul 23, 2026, 7:42 PM EDT
Completed Not applicable Interventional

Gluten Intolerance in Patients With Diarrhea Predominant Irritable Bowel Syndrome

NCT01094041
View directory record Official record
Conditions
Diarrhea, Diarrhea Predominant Irritable Bowel Syndrome
Interventions
Gluten free diet, Gluten rich diet
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 9, 2013 · Synced Jul 23, 2026, 7:42 PM EDT
Completed Phase 4 Interventional

Prospective Study of Celiac Block Injection: 1 vs. 2

NCT00583479
View directory record Official record
Conditions
Chronic Pancreatitis, Pancreatic Cancer
Interventions
one injection into the celiac ganglion, two injections into the celiac ganglion
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 11, 2012 · Synced Jul 23, 2026, 7:42 PM EDT
Completed Not applicable Interventional

Gluten Sensor Device to Promote Gluten Free Diet Adherence and Quality of Life in Patients With Celiac Disease

NCT03321214
View directory record Official record
Conditions
Celiac Disease
Interventions
Gluten Sensor Dose-Finding Intervention
Other
Lead sponsor
Columbia University
Other
Eligibility
13 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Jul 23, 2026, 7:42 PM EDT
Completed No phase listed Observational

Performance Evaluation of Capsule Endoscopy in the Diagnosis of Gluten Sensitive Enteropathy (MA-23)

NCT00555737
View directory record Official record
Conditions
Celiac Disease
Interventions
Capsule Endoscopy
Device
Lead sponsor
Medtronic - MITG
Industry
Eligibility
18 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Jul 23, 2026, 7:42 PM EDT
Completed No phase listed Observational

A Decentralized Home-Based Study To Investigate Novel Objective Biomarker Of Gluten-Mediated Symptoms In Celiac Disease Participants (CeDar ROSE Study)

NCT05686369
View directory record Official record
Conditions
Celiac Disease
Interventions
Not listed
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Jul 23, 2026, 7:42 PM EDT
Suspended No phase listed Observational Accepts healthy volunteers

Genomic Resources for Enhancing Available Therapies (GREAT1.0) Study

NCT04306939
View directory record Official record
Conditions
Chronic Pancreatitis, Inflammatory Bowel Diseases, Hepatitis, NASH - Nonalcoholic Steatohepatitis, Acute Pancreatitis, Rheumatoid Arthritis, Diabetes Mellitus, Dyslipidemias, Multiple Sclerosis, Irritable Bowel Syndrome, Chronic Pain, Chronic Disease, Chronic Kidney Diseases, Crohn Disease, Celiac Disease, Biliary Cirrhosis, Bile Acid Synthesis Defect, Gastritis, Cholecystitis, Cholelithiases, IPMN, Cyst Pancreas, Cystic Fibrosis, Pancreatic Exocrine Insufficiency, Diarrhea Chronic, Constipation - Functional, Constipation Chronic Idiopathic
Interventions
venipuncture, Questionnaires, Additional Sample Collections
Other · Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
12 Years and older
Enrollment
120,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2026
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jul 23, 2026, 7:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Predictive Genetic Risk Assessment Trial

NCT00782366
View directory record Official record
Conditions
Colon Cancer, Lung Cancer, Atrial Fibrillation, Diabetes Type 2, Obesity, Breast Cancer, Graves Disease, Osteoarthritis, Celiac Disease, Myocardial Infarction, Prostate Cancer
Interventions
SNP analysis
Genetic
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Jul 23, 2026, 7:42 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Combined Antibody Screening for Celiac and Diabetes Evaluation

NCT04677699
View directory record Official record
Conditions
Type 1 Diabetes, Celiac Disease
Interventions
Combined Risk Score
Diagnostic Test
Lead sponsor
Pacific Northwest Research Institute
Other
Eligibility
1 Day to 7 Years
Enrollment
64,410 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 20, 2020 · Synced Jul 23, 2026, 7:42 PM EDT
Completed Phase 3 Interventional

Randomized Trial of EUS Neurolysis in Pancreas Cancer

NCT00279292
View directory record Official record
Conditions
Pancreatic Neoplasms
Interventions
Celiac Plexus Neurolysis
Procedure
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Scottsdale, Arizona • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 13, 2015 · Synced Jul 23, 2026, 7:42 PM EDT
Completed Phase 2 Interventional

Dose-Ranging Study of the Efficacy and Safety of TAK-101 for Prevention of Gluten-Specific T Cell Activation in Participants With Celiac Disease on a Gluten-Free Diet

NCT04530123
View directory record Official record
Conditions
Celiac Disease
Interventions
Placebo, TAK-101, Gluten
Drug · Dietary Supplement
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
26
States / cities
Scottsdale, Arizona • Escondido, California • Poway, California + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 23, 2026, 7:42 PM EDT
Suspended Not applicable Interventional

Effects of Home Gluten Immunogenic Peptide Testing on Children With Celiac Disease

NCT03462979
View directory record Official record
Conditions
Celiac Disease, Gluten Sensitivity, Gluten Enteropathy, Gastrointestinal Disease, Digestive System Disease, Diet Modification, Intestinal Disease, Malabsorption Syndromes, Patient Compliance, Diagnostic Self Evaluation, Quality of Life
Interventions
Immunochromatographic lateral flow test
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
6 Years to 18 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Jul 23, 2026, 7:42 PM EDT
Recruiting Early Phase 1 Interventional

VTP-1000 in Adults With Celiac Disease

NCT06310291
View directory record Official record
Conditions
Celiac Disease
Interventions
VTP-1000, Matched Placebo
Biological · Other
Lead sponsor
Barinthus Biotherapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Los Angeles, California • Colorado Springs, Colorado • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 23, 2026, 7:42 PM EDT
Completed No phase listed Observational

Evaluation of Patient Reported Outcome Instruments in Celiac Disease Patients

NCT01560169
View directory record Official record
Conditions
Celiac Disease
Interventions
Not listed
Lead sponsor
Alvine Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
9
States / cities
La Jolla, California • San Diego, California • Aurora, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2013 · Synced Jul 23, 2026, 7:42 PM EDT
Completed Phase 3 Interventional

Intraoperative Celiac Plexus Neurolysis for Patients With Operable Pancreatic and Periampullary Cancer

NCT00806611
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Alcohol Block
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
438 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Jul 23, 2026, 7:42 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

General Population Level Estimation for Type 1 Diabetes Risk in Children During Routine Care Delivery

NCT04477928
View directory record Official record
Conditions
Type 1 Diabetes, Celiac Disease
Interventions
Sera and whole blood sampling, Differential Gene Expression (DGE)
Diagnostic Test
Lead sponsor
Sanford Health
Other
Eligibility
0 Minutes to 17 Years
Enrollment
33,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2031
U.S. locations
4
States / cities
Bemidji, Minnesota • Bismarck, North Dakota • Fargo, North Dakota + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2026 · Synced Jul 23, 2026, 7:42 PM EDT
Terminated Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms

NCT03569007
View directory record Official record
Conditions
Celiac Disease
Interventions
Larazotide, Matching Placebo
Drug
Lead sponsor
9 Meters Biopharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
307 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
160
States / cities
Saraland, Alabama • Scottsdale, Arizona • Tucson, Arizona + 132 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jul 23, 2026, 7:42 PM EDT
Completed No phase listed Observational

Immune Response in Celiac Disease on In-vitro Gluten Challenge

NCT01909050
View directory record Official record
Conditions
Celiac Disease
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 18, 2018 · Synced Jul 23, 2026, 7:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease Following a Gluten-Containing Meal

NCT00669825
View directory record Official record
Conditions
Celiac Disease
Interventions
ALV003, Placebo
Drug
Lead sponsor
Alvine Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Feb 18, 2010 · Synced Jul 23, 2026, 7:42 PM EDT
Completed Phase 2 Interventional

Latiglutenase as a Treatment for Celiac Disease

NCT03585478
View directory record Official record
Conditions
Celiac Disease
Interventions
Latiglutenase, Placebo
Drug · Other
Lead sponsor
Immunogenics, LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 14, 2021 · Synced Jul 23, 2026, 7:42 PM EDT